Upfront Briefing
Washington finally filled the FDA job, and biopharma got the candidate it will least enjoy explaining to a risk committee. Heidi Overton arrives from the Domestic Policy Council with a childhood vaccine-schedule executive order on her résumé and a Senate health committee sharpening its questions. The dealmakers ignored all of it. BioMarin put $275M down on a Phase 1/2a bone asset to pick a fight with AstraZeneca, which is either conviction or muscle memory. And a third death surfaced in China’s investigator-led trials, a reminder that the cheapest assets tend to be cheap for reasons.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,691.8 |
(0.7%) |
12.4% |
| Nasdaq 100 |
29,491.0 |
(1.7%) |
17.0% |
| Russell 2000 |
3,017.9 |
(1.3%) |
21.6% |
| Healthcare (XLV) |
169.7 |
1.6% |
9.1% |
| Biotech (XBI) |
160.1 |
0.4% |
31.8% |
| Nasdaq Biotech (NBI) |
6,960.3 |
0.9% |
22.0% |
| Clinical Trials (BBC) |
53.8 |
1.0% |
43.0% |
|
- Healthcare was the rotation trade rather than the story: XLV rose 1.6% as money left tech for defensives, with J&J up 2.3% to a fresh 52-week high and leading the Dow. Biotech only tagged along at XBI up 0.4%, a quarter of XLV’s move, and BioMarin’s $275M Alesta deal lifted BMRN about 2%.
- Risk came off in tech, not rates: the Nasdaq 100 fell 1.68% against the S&P’s 0.69% as Nvidia, Meta, Tesla and Oracle dropped up to 3%, while crude held above $84 after Trump on 17 August declined to extend the expired 60-day Iran truce. The 10-year eased to 4.70% and VIX finished at 15.85, so this was positioning, not panic.
- Market data: U.S. cash close Tuesday, 18 August 2026.
The Big 3
|
1
|
Trump picks Heidi Overton for FDA after three months of vacancy
|
- Trump has settled on Heidi Overton, deputy director of the White House Domestic Policy Council, as his FDA commissioner nominee, ending the vacancy left when Marty Makary resigned in May and setting up a Senate health committee fight.
- Why it matters: Overton arrives with no FDA operating history and a vaccine-policy footprint that will define her confirmation hearing; she stood behind Trump at the childhood-schedule executive order that Bill Cassidy publicly called wrong. The nearer-term question is whether Kyle Diamantas’s detente with industry survives her. Under him the agency reopened paths for Regenxbio, uniQure and Replimune, and that goodwill is personality-driven rather than codified. Layer on more than 3,000 departures over the past year and review capacity stays the binding constraint whoever runs the building. Confirmation will not be quick, so Diamantas keeps the pen through autumn. The risk sits in the interregnum, not the nominee.
- Source: STAT
- More: Endpoints; CNN
|
|
2
|
BioMarin buys Alesta for $275M to take on AstraZeneca in bone
|
- BioMarin is paying $275M upfront plus up to $215M in development and regulatory milestones for Alesta Therapeutics and its lead asset ALE1, an oral candidate in Phase 1/2a for hypophosphatasia; Alesta spins out all non-ALE1 assets first and no employees transfer.
- Why it matters: Third deal in two years, and the smallest-looking one is the most pointed. ALE1 goes straight at Strensiq, the AstraZeneca enzyme replacement therapy that anchors paediatric hypophosphatasia and which AZ has tipped for blockbuster sales off a next-generation follow-on. An oral against an injectable is the entire thesis. The caution is that BioMarin has run this play badly once already: the $270M Inozyme purchase produced an ENPP1 programme killed after a Phase 3 miss. Paying $275M cash for a Phase 1/2a asset buys the option, not the data. Shares added roughly 2% Tuesday and H.C. Wainwright trimmed its target to $59, holding at Neutral.
- Source: BioPharma Dive
- More: Fierce Biotech; Endpoints
|
| 3 | Third death surfaces in China’s opaque trials, this time in CAR-T |
- RiboX Therapeutics confirmed to Endpoints that a patient with an autoimmune disease died after receiving RXIM002, its circular RNA-based in vivo CAR-T, in an unregulated investigator-initiated trial in China — the third such death disclosed in recent weeks.
- Why it matters: Three disclosed deaths in three weeks across three modalities, AAV gene therapy, CRISPR and now in vivo CAR-T, reads as a pathway problem rather than a company problem. The common thread is China’s investigator-initiated route, which trades independent safety monitoring for speed, and that speed has been the cost argument underpinning Western licensing of China-originated assets. Order 818 tightened IIT requirements in May, after all three deaths occurred and before any surfaced. Anyone underwriting a China in-licensing deal on IIT-generated data now prices a diligence discount, and the COINS Act debate acquires a safety argument it did not have in June. The read is provenance, not mechanism.
- Source: Endpoints
- More: Fierce Biotech
|
Everything Else that broke
- Takeda's Orzeyful approval is raising competitive pressure in narcolepsy's orexin race. — BioSpace
- Novo and Lilly's oral obesity contest is turning into a long-game share fight. — BioSpace
- MHRA told users to stop using rectal catheters in infants immediately. — GOV.UK
- CARsgen posted interim cash of about RMB1,400M, keeping runway in focus. — PR
- CSL said Vifor revenue will fall about 25% on Tavneos’ EU revocation, generic iron competition and Velphoro pressure. — Endpoints
- Kolon TissueGene is cutting 37 staff after a pivotal knee osteoarthritis miss. — Fierce Biotech
- GenBio AI rolled out AIDO Cell, joining the scramble to speed discovery. — STAT
- Rebounding biotech funding could start lifting CDMO demand within a year. — BioSpace
- Amylyx’s avexitide cut severe hypoglycaemic events by more than half in Phase 3, clearing the way for a filing. — Fierce Biotech
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- BioMarin acquired an experimental rare bone disorder drug for $275M (see The Big 3). — BioPharma Dive
- Sandoz signed a $322M biosimilars rights deal with Henlius covering up to 10 assets. — BioSpace
- Piramal completed its acquisition of a controlling stake in Yapan Bio. — PR
- Curavit bought Lindus Health CRO assets to expand U.S. and Europe trial delivery. — PR
- Merck partnered with Sarah Cannon to widen access to community oncology trials. — Fierce Biotech
- Chugai granted GSK an exclusive worldwide licence to AID351, an anti-dengue antibody, with GSK running Phase 1 and manufacturing against royalties and a share of sublicensing income. — BioWorld
- Lundbeckfond Invest launched a voluntary exchange offer for H. Lundbeck A-shares. — PR
VC / Private Financings
- Beyang raised a $30M Series A; syndicate detail was not disclosed. — BioWorld
- Craif raised a $33M Series D for its urine-based cancer screening test, taking total capital raised to $88M. — Fierce Biotech
IPOs / Follow-Ons
- No notable IPOs or follow-ons in the last 24 hours.
Academic Corner - Nature Biotech spotlighted Dispatch Bio, which delivers antigens to solid tumors for CAR-T immunotherapy. — Nature Biotech
- A Nature Biotech analysis mapped how drug revenue life cycles vary across modalities and therapeutic areas. — Nature Biotech
- Nature Medicine argued food-as-medicine could reshape nutrition care in oncology. — Nature Medicine
|
